Skip Navigation



American Journal of Epidemiology Advance Access published online on October 9, 2008
American Journal of Epidemiology, doi:10.1093/aje/kwn257
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
168/11/1319    most recent
kwn257v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Weiss, J. M.
Right arrow Articles by Zheng, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiss, J. M.
Right arrow Articles by Zheng, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology © The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.

Original Contribution

Menstrual and Reproductive Factors in Association With Lung Cancer in Female Lifetime Nonsmokers

Jocelyn M. Weiss, James V. Lacey, Jr., Xiao-Ou Shu, Bu-Tian Ji, Lifang Hou, Gong Yang, Honglan Li, Nathaniel Rothman, Aaron Blair, Yu-Tang Gao, Wong-Ho Chow and Wei Zheng

Correspondence to Dr. Jocelyn Weiss, International Epidemiology Institute, 1455 Research Boulevard, Suite 550, Rockville, MD 20850 (e-mail: jocelyn{at}iei.us).

Received for publication February 27, 2008. Accepted for publication July 25, 2008.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 References
 
Cigarette smoking is irrefutably the strongest risk factor for lung cancer; however, approximately 25% of cases worldwide occur among nonsmokers. The age-adjusted annual incidence rate of lung cancer in Shanghai, a region where relatively few women smoke cigarettes, is one of the highest in the world. To help further elucidate the etiology of lung cancer among nonsmokers, the authors examined hormonal factors among women who were lifetime nonsmokers. They analyzed data from the prospective Shanghai Women's Health Study, which recruited Chinese women aged 40–70 years between 1996 and 2000 from selected urban communities. The current analysis included 71,314 women (n = 220 cases) who were lifetime nonsmokers and had no history of cancer at baseline. Later age at menopause (≥51 vs. <46 years; hazard ratio (HR) = 0.63, 95% confidence interval (CI): 0.40, 1.00), longer reproductive period (≥36 vs. <31 years; HR = 0.60, 95% CI: 0.39, 0.93), higher parity (≥4 vs. 0 children; HR = 0.42, 95% CI: 0.19, 0.90), and intrauterine device use (HR = 0.59, 95% CI: 0.41, 0.86) were associated with decreased risks of lung cancer. This large prospective study suggests a potential role for hormonal factors in the etiology of lung cancer among nonsmoking women.

hormones; lung; menstrual cycle; neoplasms; parity

Abbreviations: CI, confidence interval; HR, hazard ratio


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 References
 
Smoking is a strong risk factor for lung cancer, and 85%–90% of lung cancer deaths are attributable to cigarette smoking (1). The remaining 10%–15% occur among nonsmokers, so other factors are likely involved in the etiology of this disease. Candidate contributors include secondhand smoke exposure, air pollution, occupational exposures (e.g., arsenic, asbestos, radon, tar, chromium), cooking practices (e.g., use of solid fuels and high-temperature frying), family history of cancer, prior lung disease, and dietary components, as shown by review (2). Among female nonsmokers, reproductive and hormonal exposures have also been proposed to play a role (3, 4), but these variables have not been well studied, and thus a role for these factors has not been clearly established.

Estrogen could influence cancer development through direct promotion of cellular proliferation in the lung. Estrogen metabolites could also induce direct DNA damage (5). Indirectly, hormones could act through their influence on the expression of genes involved in carcinogen metabolism or via regulation of cytokine or growth factor secretion that determine how the lungs respond to irritants (6). The biologic plausibility of hormonal involvement in lung carcinogenesis is supported by studies that have identified sex hormone receptors (estrogen and progesterone) in lung cancer cell lines and tumor tissues (7–10). Few epidemiologic studies, however, have examined hormonal and reproductive risk factors for lung cancer, and the findings have not been consistent (11–22).

Lung cancer incidence and mortality rates among men have dropped over the last decade, but not among women. The death rate in females has increased 600% since 1950 in the United States (23). Differences in incidence and mortality between the sexes could reflect differences in susceptibility to disease and disease progression, but this notion is controversial (24–28). The most recent analysis of 2 large American Cancer Society Prevention Study cohorts (CPS-I and CPS-II) did not observe sex differences in lung cancer mortality among nonsmokers (27). It has been estimated, however, that anywhere from 3% to 15% of men and from 33% to 53% of all women with lung cancer worldwide are never smokers (6, 29). It is unclear whether the higher incidence among female nonsmokers is due to differences in exposure or susceptibility between men and women. Adenocarcinoma of the lung, shown to have a weaker association with tobacco smoking than other histologic types of lung cancer, is also observed predominantly in women, suggesting a possible role for female hormones in this form of the disease (30, 31). To help further elucidate the etiology of lung cancer among nonsmokers, we examined hormonal factors among women who were lifetime nonsmokers.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 References
 
The Shanghai Women's Health Study
From 1996 to 2000, 74,942 Chinese women aged 40–70 years were recruited to participate in the prospective Shanghai Women's Health Study. The cohort, enrollment, and follow-up have previously been described in detail (32). In brief, the study was conducted in 7 urban communities in Shanghai, with rosters of all eligible women who lived in these communities obtained from the resident offices. The incidence rates of major cancers, as well as the distributions of age, sex, educational level, and occupation of the study population, were similar to those of the entire population of urban Shanghai (32). Of 81,170 eligible women who lived in the study communities during the time period of the baseline survey, 75,221 (92.7%) participated in the study. Between 2001 and 2004, 74,942 (99.6%) of these women completed the first follow-up survey. The cohort has been followed for mortality and cancer incidence by using a combination of record linkage and active follow-up. Interviewers visit each participant every 2 years to update health history and lifestyle factors. Cancer diagnoses and deaths are verified through medical chart review.

Study population
We excluded women with a history of cancer at study entry (n = 1,576) and those missing information on the date at first follow-up (n = 8). Of the remaining 73,358 eligible women, 71,314 (97%) were lifetime nonsmokers and were included in the current analysis. Incident cases (n = 220) were diagnosed between 1996 and December 2005 with malignant neoplasm of the bronchus or lung (International Classification of Diseases, Ninth Revision, codes 162.0–162.9).

Baseline exposure assessment
All participants completed a 2-part questionnaire at study enrollment. Part 1 of the questionnaire was self-administered, and part 2 was interview administered. Study participants completed the self-administered questionnaire that included questions on demographics, current and past smoking behavior, medical history and medication use, menstrual history, family history of cancer, occupational history, and spousal information (including smoking). Interviewers then reviewed the completeness and accuracy of the self-administered questionnaires and administered the second part of the baseline survey. Information was collected on dietary habits, reproductive history and hormone use, passive smoke exposure at home and at work, physical activity over the past 5 years and during adolescence, and weight and height history. Interviewers obtained anthropometric measurements and collected blood and urine samples. With respect to passive smoke exposure, information was collected at baseline for exposures through the husband and at the workplace. Information on smoking in the home before and after the age of 20 years (years, cigarettes per day, hours per day) was obtained at first follow-up, which took place approximately 2 years after baseline for most participants.

Statistical analyses
The association between various hormonal factors and risk of lung cancer was evaluated by using Cox proportional hazards with age as the time scale and stratification by birth cohort (5-year intervals). Exposure variables included menopausal status (premenopausal, postmenopausal), age at menarche (<15, 15–16, ≥17 years), age at menopause (<46, 46–48, 49–50, ≥51 years), reproductive period (<31, 31–33, 34–35, ≥36 years), parity (0, 1–3, ≥4 births), age at first birth (<23, 23–25, 26–27, ≥28 years), intrauterine device use (never/ever), oral contraceptive use (never/ever), and postmenopausal hormone use (never/ever). Change in menopausal status after baseline was accounted for by splitting the follow-up time at the date of menopause. The reproductive period was calculated as the years between menarche and menopause.

The factors evaluated as potential confounders included age, education, marital status, income, body mass index, family history of cancer, history of respiratory disease, passive smoke exposure, alcohol consumption, cooking fuel/oil, nutritional factors, and the exposure variables. Passive smoke exposure was defined as ever exposure in the home or workplace. Nutritional factors were modeled as categorical variables defined by the quartile distributions among controls. Covariates were evaluated as potential confounders by assessing whether their inclusion altered risk estimates by >10%.

The risk of lung cancer associated with age at menarche and age at menopause was also modeled with stratification by passive smoke exposure. To test for linear trends in hazard ratios across groups, we created score variables representing the median of each category and included them into the Cox models as continuous variables. For dichotomous variables, Wald's P values indicate the significance of trend between the respective levels. Likelihood ratio tests were performed to test for multiplicative interactions. All analyses were performed by using the STATA 9.0 statistical package (StataCorp LP, College Station, Texas).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 References
 
A total of 506,522 person-years were accrued in this population of female lifetime nonsmokers. Cases were followed for an average of 4.1 years from study entry to diagnosis. Cases were significantly older than the cohort but were similar with respect to educational level, marital status, family history of cancer, alcohol consumption, and adult exposure to passive smoke (Table 1). Although excluded from analyses, ever smokers had a 2-fold increased risk of lung cancer (hazard ratio (HR) = 2.38, 95% confidence interval (CI): 1.54, 3.68; results not shown).


View this table:
[in this window]
[in a new window]

  		Table 1. Associations of Lung Cancer Diagnosed Between 1996 and 2005 and Selected Risk Factors Among Female Nonsmokers, Shanghai Women's Health Study

 
A later age at menarche (≥17 vs. <15 years; HR = 1.38, 95% CI: 0.94, 2.04) was associated with a nonsignificantly increased risk of lung cancer (Table 2). Decreased risk was observed among women with a later age at menopause (≥51 vs. <46 years; HR = 0.63, 95% CI: 0.40, 1.00; Ptrend = 0.03), longer reproductive period (years between menarche and menopause, ≥36 vs. <31 years; HR = 0.60, 95% CI: 0.39, 0.93; Ptrend < 0.01), higher parity (≥4 vs. 0 children; HR = 0.42, 95% CI: 0.19, 0.90; Ptrend < 0.01), and intrauterine device use (HR = 0.59, 95% CI: 0.41, 0.86; Ptrend = 0.01). Lung cancer risk was not associated with menopausal status, age at first birth, use of oral contraceptives, or use of postmenopausal hormone therapy. Similar results and trends were observed when analyses were restricted to women with natural menopause (results not shown).


View this table:
[in this window]
[in a new window]

  		Table 2. Associations of Lung Cancer Diagnosed Between 1996 and 2005 and Menstrual and Reproductive Factors Among Female Nonsmokers, Shanghai Women's Health Study

 
Of 220 diagnosed cases, data on histologic types were available for 168 cases (76%). Of the cases with histologic confirmation, 78 women were diagnosed with adenocarcinoma of the lung. Similar, even slightly more pronounced, associations were observed in women diagnosed with adenocarcinoma compared with all histologic subtypes combined (Table 2).

Risk estimates were comparable when analyses were stratified by passive smoke exposure, with multiplicative tests for interaction not significant (P > 0.05; Table 3).


View this table:
[in this window]
[in a new window]

  		Table 3. Associations of Lung Cancer Diagnosed Between 1996 and 2005 and Ages at Menarche and Menopause Stratified by Exposure to Passive Smoke,a Shanghai Women's Health Study

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
References
 
In our study, the risk of lung cancer among female lifetime nonsmokers was decreased among those with increased parity, later age at menopause, and longer length of reproductive years. The decreased risk associated with a longer reproductive period was similar, or slightly more pronounced, among women with adenocarcinoma of the lung.

A role for female sex hormones in the etiology of lung cancer has been suggested by other studies, but not all of the findings are consistent with ours. Most epidemiologic studies conducted to date have been modest in size, with nonsignificant findings, and have included both smokers and nonsmokers. There are similar distributions of studies reporting increased and decreased risks associated with an earlier age at menarche, a later age at menopause, a longer reproductive period, and an increased parity (11–22). With respect to prospective studies, a cohort analysis of Japanese female nonsmokers observed an increased risk of lung cancer with early age at menarche and late age at menopause (17). Contrary to our findings, those of a recent study of female Canadian smokers and nonsmokers showed increased risks of lung cancer among women with a higher parity and an earlier age at first livebirth (14). Case-control studies have also reported conflicting results. Similar to our findings, those of 2 studies from East Asia demonstrated reduced risks of lung adenocarcinoma among women with longer menstrual cycle length (13, 18) and higher parity (18); however, there were no associations of age at menarche or age at menopause. These studies are similar to ours, with one of them conducted in Shanghai (13) and the other observing the strongest decreased risks among lifetime nonsmokers and adenocarcinoma cases (18). Another Chinese study (11) observed findings similar to ours for later age at menopause; however, later age at menarche was also associated with a decreased risk, and there were no associations for length of menstrual cycle or parity. Contrary to our results, those of studies conducted in both the United States (19) and China (21) demonstrated increased risks of adenocarcinoma among women with a later age at menopause. However, no associations were observed between the age at menarche or parity and lung cancer. The retrospective designs, inclusion of smokers, and modest sample sizes (with the exception of 1 study (21)) could have contributed to the disparate findings reported in these studies compared with ours.

The relatively small effect of direct smoking observed in this cohort is similar to that reported by prior studies in other Chinese populations (13, 14, 20, 21). Estimates tend to be much higher among current smokers than among former smokers or ever smokers (current and former combined) and, in this study, women were classified as ever/never smokers.

Our findings of a lower risk of lung cancer among women with a normal or later age at menopause compared with those women who underwent earlier menopause (<46 years of age) suggest that there is something about an early age at menopause that increases risk. One possible explanation is that a greater proportion of women who underwent earlier age at menopause did so through surgical means and thus were different from women who experienced a later age at natural menopause. Similar results, however, were observed when analyses were restricted to women who experienced natural menopause. The findings for age at menarche also hold up when restricted to women with a later age at menopause, suggesting that features of both menarche and menopause might be important.

The mechanism through which menstrual factors could influence lung cancer risk is not entirely clear. It has been hypothesized that ages at menarche and menopause are markers of nutritional status (33, 34). However, risk estimates were not attenuated after adjustment for various nutritional factors. A potential mechanism through which menstrual factors could influence risk is by the role of estrogens in epithelial cell regeneration and maintenance. Localized estrogen receptors are important for cellular maintenance in the lung (35, 36). Surfactant, produced in alveolar type II cells, is essential for normal lung function; it clears the lungs of unwanted particles, including carcinogens. Lungs from adult female estrogen receptor-beta knockout mice have larger, yet fewer alveoli than their wild-type littermates and accumulate surfactant inside the alveolar spaces (36). In addition, sex differences in immune function suggest that hormonal influences play a role. Women have higher systemic immunity and are more susceptible to autoimmune diseases than are men (37, 38). In murine models, treatment of normal mice with estrogen leads to the induction of antibodies (39–42). In vivo and in vitro models demonstrate the role of estrogens in influencing the cytokine milieu toward pro- (type I) or antiinflammatory (type II) cytokines (37). Interstitial lung disease, characterized by chronic inflammation and fibrosis, is hypothesized to predispose to lung carcinogenesis via repeated cellular injury and genetic damage to local epithelial cells. Therefore, a mechanistic link among estrogen exposure, inflammation in the lung, and lung cancer is biologically plausible.

The main strength of our study is the inclusion of a large number of nonsmoking women with information on passive smoke exposure. Participants have been followed prospectively with a high rate of follow-up. There are, however, some limitations. Although our sample size as a whole is large, the number of cases accrued to date is modest. In addition, we were not sufficiently powered to examine the associations of exogenous hormone use on risk, since few women in our study population were exposed. Self-reported ages at menopause and menarche are subject to misclassification, but we expected that to be random and, thus, they serve only to attenuate the observed risk estimates. Finally, although we included ever exposure to passive smoke (at home or in the workplace) in the model, we acknowledge that this may not have fully controlled for confounding given that there was no overall association. Although a stronger association was observed when women were classified on exposure at work alone, adjustment for workplace exposure did not materially alter risk estimates. In addition, although less dramatic effects were observed among women who reported no passive smoke exposure, the number of cases and total person-years are much lower than those for women who reported exposure to passive smoke.

The risk of lung cancer among female lifetime nonsmokers was decreased for women with a later age at menopause, a longer reproductive period, and an increased parity. Later age at menarche was associated with increased risk. These findings suggest a potential role for hormonal factors in the etiology of lung cancer in nonsmoking women. The accumulating laboratory evidence is likely sufficient to justify targeted molecular epidemiologic analyses that test these hypotheses among nonsmoking women whose reproductive history and exposure to exogenous estrogen are well-characterized.


   ACKNOWLEDGMENTS
 
Author affiliations: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (Jocelyn M. Weiss, James V. Lacey, Jr., Bu-Tian Ji, Nathaniel Rothman, Aaron Blair, Wong-Ho Chow); Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee (Xiao-Ou Shu, Gong Yang, Wei Zheng); Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Lifang Hou); and Department of Epidemiology, Shanghai Cancer Institute, Shanghai, People's Republic of China (Honglan Li, Yu-Tang Gao).

Conflict of interest: none declared.


   References
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 References
 

  1. Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. MMWR Morb Mortal Wkly Rep (2005) 54(25):625–628.[Medline]
  2. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest (2003) 123(1 suppl):21S–49S.[CrossRef][Web of Science][Medline]
  3. Brownson RC, Alavanja MC, Caporaso N, et al. Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol Rev. (1998) 20(2):218–236.[Free Full Text]
  4. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. (2007) 25(5):561–570.[Abstract/Free Full Text]
  5. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis (1998) 19(1):1–27.[Abstract/Free Full Text]
  6. Siegfried JM. Women and lung cancer: does oestrogen play a role? Lancet Oncol. (2001) 2(8):506–513.[CrossRef][Medline]
  7. Cagle PT, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res. (1990) 50(20):6632–6635.[Abstract/Free Full Text]
  8. Canver CC, Memoli VA, Vanderveer PL, et al. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg. (1994) 108(1):153–157.[Abstract/Free Full Text]
  9. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer (1996) 67(3):357–364.[CrossRef][Web of Science][Medline]
  10. Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med. (1994) 118(6):630–632.[Web of Science][Medline]
  11. Brenner AV, Wang Z, Kleinerman RA, et al. Menstrual and reproductive factors and risk of lung cancer among Chinese women, Eastern Gansu Province, 1994–1998. J Epidemiol. (2003) 13(1):22–28.[Web of Science][Medline]
  12. Elliott AM, Hannaford PC. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners’ Oral Contraception Study. Contraception (2006) 73(4):331–335.[CrossRef][Web of Science][Medline]
  13. Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer (1987) 40(5):604–609.[Web of Science][Medline]
  14. Kabat GC, Miller AB, Rohan TE. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer (2007) 120(10):2214–2220.[CrossRef][Web of Science][Medline]
  15. Kreuzer M, Gerken M, Heinrich J, et al. Hormonal factors and risk of lung cancer among women? Int J Epidemiol. (2003) 32(2):263–271.[Abstract/Free Full Text]
  16. Liao ML, Wang JH, Wang HM, et al. A study of the association between squamous cell carcinoma and adenocarcinoma in the lung, and history of menstruation in Shanghai women, China. Lung Cancer (1996) 14(suppl_1):S215–S221.[Web of Science][Medline]
  17. Liu Y, Inoue M, Sobue T, et al. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer (2005) 117(4):662–666.[CrossRef][Web of Science][Medline]
  18. Seow A, Poh WT, Teh M, et al. Diet, reproductive factors and lung cancer risk among Chinese women in Singapore: evidence for a protective effect of soy in nonsmokers. Int J Cancer (2002) 97(3):365–371.[CrossRef][Web of Science][Medline]
  19. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women [letter]. J Natl Cancer Inst. (1994) 86(11):869–870.[Free Full Text]
  20. Wu AH, Yu MC, Thomas DC, et al. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res. (1988) 48(24 pt 1):7279–7284.[Abstract/Free Full Text]
  21. Wu-Williams AH, Dai XD, Blot W, et al. Lung cancer among women in north-east China. Br J Cancer (1990) 62(6):982–987.[Web of Science][Medline]
  22. Zhou BS, Wang TJ, Guan P, et al. Indoor air pollution and pulmonary adenocarcinoma among females: a case-control study in Shenyang, China. Oncol Rep. (2000) 7(6):1253–1259.[Web of Science][Medline]
  23. The health consequences of smoking for women. A report of the Surgeon General. (1980) Washington, DC: Office on Smoking and Health, Office of the Assistant Secretary for Health, Public Health Service, US Department of Health and Human Services. (http://profiles.nlm.nih.gov/NN/B/B/R/T/_/nnbbrt.pdf).
  24. Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst. (2004) 96(11):826–834.[Abstract/Free Full Text]
  25. Novello S, Baldini E. Women and lung cancer. Ann Oncol. (2006) 17(suppl 2):ii79–ii82.[Free Full Text]
  26. Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol. (1993) 138(5):281–293.[Abstract/Free Full Text]
  27. Thun MJ, Henley SJ, Burns D, et al. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst. (2006) 98(10):691–699.[Abstract/Free Full Text]
  28. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. (1996) 88(3–4):183–192.[Abstract/Free Full Text]
  29. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin. (2005) 55(2):74–108.[Abstract/Free Full Text]
  30. Baldini EH, Strauss GM. Women and lung cancer: waiting to exhale. Chest (1997) 112(4 suppl):229S–234S.[CrossRef][Medline]
  31. Kirsh MM, Tashian J, Sloan H. Carcinoma of the lung in women. Ann Thorac Surg. (1982) 34(1):34–39.[Abstract]
  32. Zheng W, Chow WH, Yang G, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol. (2005) 162(11):1123–1131.[Abstract/Free Full Text]
  33. Nagel G, Altenburg HP, Nieters A, et al. Reproductive and dietary determinants of the age at menopause in EPIC-Heidelberg. Maturitas (2005) 52(3–4):337–347.[CrossRef][Web of Science][Medline]
  34. Thomas F, Renaud F, Benefice E, et al. International variability of ages at menarche and menopause: patterns and main determinants. Hum Biol. (2001) 73(2):271–290.[Web of Science][Medline]
  35. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology (1997) 138(3):863–870.[Abstract/Free Full Text]
  36. Patrone C, Cassel TN, Pettersson K, et al. Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol. (2003) 23(23):8542–8552.[Abstract/Free Full Text]
  37. Nalbandian G, Kovats S. Estrogen, immunity & autoimmune disease. Curr Med Chem Immunol Endocrinol Metab. (2005) 5:85–91.[CrossRef]
  38. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol. (2001) 1(6):983–993.[CrossRef][Web of Science][Medline]
  39. Ahmed SA, Verthelyi D. Antibodies to cardiolipin in normal C57BL/6J mice: induction by estrogen but not dihydrotestosterone. J Autoimmun. (1993) 6(3):265–279.[CrossRef][Web of Science][Medline]
  40. Verthelyi D, Ahmed SA. 17β-Estradiol, but not 5{alpha}-dihydrotestosterone, augments antibodies to double-stranded deoxyribonucleic acid in nonautoimmune C57BL/6J mice. Endocrinology (1994) 135(6):2615–2622.[Abstract]
  41. Verthelyi D, Ansar Ahmed S. Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice. J Autoimmun. (1997) 10(2):115–125.[CrossRef][Web of Science][Medline]
  42. Verthelyi DI, Ahmed SA. Estrogen increases the number of plasma cells and enhances their autoantibody production in nonautoimmune C57BL/6 mice. Cell Immunol. (1998) 189(2):125–134.[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Seow, W.-P. Koh, R. Wang, H.-P. Lee, and M. C. Yu
Reproductive Variables, Soy Intake, and Lung Cancer Risk among Nonsmoking Women in the Singapore Chinese Health Study
Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 821 - 827.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
168/11/1319    most recent
kwn257v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Weiss, J. M.
Right arrow Articles by Zheng, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiss, J. M.
Right arrow Articles by Zheng, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?